STOCK TITAN

[Form 4] Generation Bio Co. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Generation Bio (GBIO) reported an insider transaction by its Chief Financial Officer on 10/15/2025. The filing shows 58 shares of common stock were acquired following the settlement of restricted stock units (Code M), and 18 shares were disposed of at $6.71 (Code F). Following these transactions, the officer directly owned 1,867 shares.

The report notes a one-for-10 reverse stock split effected on July 21, 2025. It also references a grant of 939 restricted stock units made on January 20, 2023, with 25% vested on January 15, 2024, and the remainder vesting in equal quarterly installments thereafter.

Generation Bio (GBIO) ha riportato una operazione interna del suo Direttore Finanziario il 15/10/2025. La dichiarazione mostra 58 azioni ordinarie acquistate dopo la liquidazione di unità di azioni vincolate (Codice M), e 18 azioni sono state liquidate a $6,71 (Codice F). A seguito di queste operazioni, l'ufficiale possedeva direttamente 1.867 azioni.

Il rapporto segnala un frazionamento inverso di 1-10 effettuato il 21 luglio 2025. Riferisce anche a una concessione di 939 unità di azioni vincolate assegnata il 20 gennaio 2023, con il 25% vestito il 15 gennaio 2024, e il resto vestito in rate trimestrali uguali in seguito.

Generation Bio (GBIO) informó una operación interna de su Directorio Financiero el 15/10/2025. La declaración muestra 58 acciones ordinarias adquiridas tras la liquidación de unidades de acciones restringidas (Código M), y 18 acciones fueron vendidas a $6.71 (Código F). Tras estas operaciones, el funcionario poseía directamente 1,867 acciones.

El informe señala un split inverso de 1 por 10 implementado el 21 de julio de 2025. También hace referencia a una concesión de 939 unidades de acciones restringidas otorgada el 20 de enero de 2023, con el 25% vestidas el 15 de enero de 2024, y el resto vesting en cuotas trimestrales iguales en adelante.

Generation Bio (GBIO)2025년 10월 15일에 CFO의 내부 거래를 보고했습니다. 신고서에는 58주식의 일반주식이 제한 주식단위(Code M)의 정산 후 취득되었고, 18주식$6.71에 매각되었다고 명시되어 있습니다(Code F). 이 거래들 후 해당 임원은 직접 1,867주의 주식을 보유했습니다.

또한 보고서는 1대 10 역분할이 2025년 7월 21일에 시행되었다고 언급합니다. 또한 2023년 1월 20일에 부여된 939개의 제한주식단위의 부여를 참조하며, 25%는 2024년 1월 15일에 가속 vesting되었고, 나머지는 이후 분기별로 동일한 비율로 vesting됩니다.

Generation Bio (GBIO) a signalé une transaction interne de son Directeur financier le 15/10/2025. Le dépôt indique que 58 actions ordinaires ont été acquises à la suite du règlement d’unités d’actions restreintes (Code M), et 18 actions ont été vendues à $6,71 (Code F). Suite à ces transactions, le dirigeant détenait directement 1 867 actions.

Le rapport note une division inverse de 1 pour 10 effectuée le 21 juillet 2025. Il fait également référence à une attribution de 939 unités d’actions restreintes accordée le 20 janvier 2023, dont 25% sont devenues acquises le 15 janvier 2024, et le reste acquise par tranches trimestrielles égales par la suite.

Generation Bio (GBIO) meldete eine Insider-Transaktion seines Chief Financial Officer am 15.10.2025. Die Meldung zeigt 58 Stammaktien wurden nach der Abwicklung von Restricted Stock Units (Code M) erworben, und 18 Aktien wurden zu $6,71 (Code F) veräußert. Nach diesen Transaktionen besaß der Beauftragte direkt 1.867 Aktien.

Der Bericht vermerkt einen 1-für-10-Reverse-Split, der am 21. Juli 2025 durchgeführt wurde. Er verweist auch auf eine Gewährung von 939 Restricted Stock Units, die am 20. Januar 2023 gewährt wurde, von denen 25% am 15. Januar 2024 fällig wurden, der Rest in gleichen vierteljährlichen Raten anschließend.

Generation Bio (GBIO) أبلغت عن صفقة داخلية لرئيسها المالي في 15/10/2025. يظهر الإيداع أن 58 سهماً عادياً تم اكتسابها عقب تسوية وحدات الأسهم المقيدة (رمز M)، وأن 18 سهماً تم التصرف بها عند $6.71 (رمز F). بعد هذه المعاملات، كان لدى المسؤول ملكية مباشرة لـ 1,867 سهماً.

يشير التقرير إلى قسمة عكسية 1 مقابل 10 أُجريت في 21 يوليو 2025. كما يذكر منحاً قدره 939 وحدة أسهم مقيدة مُنحت في 20 يناير 2023، حيث تم vesting 25% في 15 يناير 2024، والباقي يتوزع بالتساوي على دفعات ربع سنوية لاحقة.

Generation Bio (GBIO) 报告称其首席财务官在 2025/10/15 进行了一笔内部交易。文件显示在结算受限股票单位(代码 M)后获得了 58 股普通股,并且以 $6.71(代码 F)处置了 18 股。这些交易后,该官员直接拥有 1,867 股

报告还提到在 2025/7/21 实施的 一对十反向合股。另提到在 2023/1/20 授予的 939 股限制性股票单位,其中 25% 在 2024/1/15 已归属,其余按季度等额归属。

Positive
  • None.
Negative
  • None.

Generation Bio (GBIO) ha riportato una operazione interna del suo Direttore Finanziario il 15/10/2025. La dichiarazione mostra 58 azioni ordinarie acquistate dopo la liquidazione di unità di azioni vincolate (Codice M), e 18 azioni sono state liquidate a $6,71 (Codice F). A seguito di queste operazioni, l'ufficiale possedeva direttamente 1.867 azioni.

Il rapporto segnala un frazionamento inverso di 1-10 effettuato il 21 luglio 2025. Riferisce anche a una concessione di 939 unità di azioni vincolate assegnata il 20 gennaio 2023, con il 25% vestito il 15 gennaio 2024, e il resto vestito in rate trimestrali uguali in seguito.

Generation Bio (GBIO) informó una operación interna de su Directorio Financiero el 15/10/2025. La declaración muestra 58 acciones ordinarias adquiridas tras la liquidación de unidades de acciones restringidas (Código M), y 18 acciones fueron vendidas a $6.71 (Código F). Tras estas operaciones, el funcionario poseía directamente 1,867 acciones.

El informe señala un split inverso de 1 por 10 implementado el 21 de julio de 2025. También hace referencia a una concesión de 939 unidades de acciones restringidas otorgada el 20 de enero de 2023, con el 25% vestidas el 15 de enero de 2024, y el resto vesting en cuotas trimestrales iguales en adelante.

Generation Bio (GBIO)2025년 10월 15일에 CFO의 내부 거래를 보고했습니다. 신고서에는 58주식의 일반주식이 제한 주식단위(Code M)의 정산 후 취득되었고, 18주식$6.71에 매각되었다고 명시되어 있습니다(Code F). 이 거래들 후 해당 임원은 직접 1,867주의 주식을 보유했습니다.

또한 보고서는 1대 10 역분할이 2025년 7월 21일에 시행되었다고 언급합니다. 또한 2023년 1월 20일에 부여된 939개의 제한주식단위의 부여를 참조하며, 25%는 2024년 1월 15일에 가속 vesting되었고, 나머지는 이후 분기별로 동일한 비율로 vesting됩니다.

Generation Bio (GBIO) a signalé une transaction interne de son Directeur financier le 15/10/2025. Le dépôt indique que 58 actions ordinaires ont été acquises à la suite du règlement d’unités d’actions restreintes (Code M), et 18 actions ont été vendues à $6,71 (Code F). Suite à ces transactions, le dirigeant détenait directement 1 867 actions.

Le rapport note une division inverse de 1 pour 10 effectuée le 21 juillet 2025. Il fait également référence à une attribution de 939 unités d’actions restreintes accordée le 20 janvier 2023, dont 25% sont devenues acquises le 15 janvier 2024, et le reste acquise par tranches trimestrielles égales par la suite.

Generation Bio (GBIO) meldete eine Insider-Transaktion seines Chief Financial Officer am 15.10.2025. Die Meldung zeigt 58 Stammaktien wurden nach der Abwicklung von Restricted Stock Units (Code M) erworben, und 18 Aktien wurden zu $6,71 (Code F) veräußert. Nach diesen Transaktionen besaß der Beauftragte direkt 1.867 Aktien.

Der Bericht vermerkt einen 1-für-10-Reverse-Split, der am 21. Juli 2025 durchgeführt wurde. Er verweist auch auf eine Gewährung von 939 Restricted Stock Units, die am 20. Januar 2023 gewährt wurde, von denen 25% am 15. Januar 2024 fällig wurden, der Rest in gleichen vierteljährlichen Raten anschließend.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Conway Kevin John

(Last) (First) (Middle)
C/O GENERATION BIO CO.
301 BINNEY ST, SUITE 401

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Generation Bio Co. [ GBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 M 58(1) A (2) 1,885(1) D
Common Stock 10/15/2025 F 18(1) D $6.71 1,867(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 10/15/2025 M 58(1) (3) (3) Common Stock 58(1) $0 294(1) D
Explanation of Responses:
1. Amounts reported in this Form 4 reflect the one-for-10 reverse stock split effected by the issuer on July 21, 2025.
2. Each restricted stock unit represents the right to receive one share of the company's common stock.
3. The grant of 939 restricted stock units was made on January 20, 2023. The shares underlying the restricted stock units vest over four years, with 25% of the shares vested on January 15, 2024 and the remaining shares vesting in equal quarterly installments thereafter.
/s/ Shawna-Gay White, Attorney-in-Fact 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Generation Bio Co.

NASDAQ:GBIO

GBIO Rankings

GBIO Latest News

GBIO Latest SEC Filings

GBIO Stock Data

44.72M
5.77M
14.24%
62.31%
2.9%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE